Citadel Advisors
ELVN icon

Citadel Advisors’s Enliven Therapeutics ELVN Stock Holding History

Citadel Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,100
Closed -$1.42M – 13963
2026
Q1 		$1.42M Buy
+36,100
New +$1M ﹤0.01% 6851
2025
Q2 		– Sell
-200
Closed -$3.94K – 13160
2025
Q1 		$3.94K Sell
200
-900
-82% -$19.4K ﹤0.01% 13928
2024
Q4 		$24.8K Buy
1,100
+1,000
+1,000% +$25.9K ﹤0.01% 13036
2024
Q3 		$2.55K Sell
100
-3,500
-97% -$81.1K ﹤0.01% 13738
2024
Q2 		$84.1K Buy
+3,600
New +$75.8K ﹤0.01% 11153
2023
Q4 		– Sell
-175
Closed -$2.39K – 14496
2023
Q3 		$2.39K Hold
175
– – ﹤0.01% 13728
2023
Q2 		$3.57K Sell
175
-2,350
-93% -$47.5K ﹤0.01% 13681
2023
Q1 		$55.3K Sell
2,525
-4,900
-66% -$99.7K ﹤0.01% 12028
2022
Q4 		$121K Sell
7,425
-250
-3% -$4K ﹤0.01% 10940
2022
Q3 		$70K Buy
+7,675
New +$45.3K ﹤0.01% 11384

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's ELVN Position: Q2 2026 in Review

Citadel Advisors increased its Enliven Therapeutics (ELVN) stake by 19% in Q2 2026, buying an estimated $13.8M and bringing the position to 2,068,992 shares worth $105M. The position accounts for 0.01% of the portfolio, ranked #944.

Citadel Advisors first reported a position in ELVN in Q1 2020 and has held it in 17 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Citadel Advisors held 2,068,992 shares of Enliven Therapeutics worth $105M as of Q2 2026.
  • Citadel Advisors bought 325,077 Enliven Therapeutics shares in Q2 2026, an estimated $13.8M.
  • Enliven Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #944 holding.
  • Citadel Advisors first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.